-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Alibaba Health (00241) falls more than 7% and will release interim results next week. Previously, many major banks lowered their 2027 performance expectations

Zhitongcaijing·11/18/2026 03:17:02
Listen to the news

The Zhitong Finance App learned that Ali Health (00241) fell by more than 7%. As of press release, it was down 7.11% to HK$2.68, with a turnover of HK$276 million.

According to the news, Alibaba Health plans to hold a board meeting on November 24 (next Tuesday) to consider and approve (including) the interim results of the company and its subsidiaries for the six months ended September 30, 2026. CICC previously stated that during the first half of fiscal year 2027, the bank observed stricter regulations on overseas health products, and sales of industry products were generally under pressure. The bank determined that the company's health products category was also negatively affected. It is worth noting that since September of this year, a number of major banks have successively lowered the company's performance expectations and target prices for the 2027 fiscal year.

Lyon released a research report in early October saying that Ali Health lowered its revenue forecast for the 2027 fiscal year, mainly due to weak sales of nutritional products due to subsidy cuts and regulatory headwinds, while drug sales are still steady, with a 10-digit increase over the previous year. The bank lowered its adjusted net profit forecast for the 2027-2028 fiscal year by 6% to 7%, and lowered the target price from HK$4.7 to HK$3.7, maintaining the “outperforming the market” rating.